+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2026-2032- Product Image
Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2026-2032- Product Image
Sale

Oral Solid Dosage Contract Manufacturing Market - Global Forecast 2026-2032

  • Report

  • 181 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5666205
UP TO OFF until Dec 31st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Solid Dosage Contract Manufacturing Market is projected to reach USD 11.77 Billion in 2026. It is expected to continue growing at a CAGR of 9.15%, reaching USD 19.96 Billion by 2032.

Oral solid dosage contract manufacturing is a critical pillar of pharmaceutical outsourcing, supporting the development and commercial production of tablets, capsules, powders, granules, pellets, and modified-release formulations. Demand is being shaped by the continued importance of oral medicines in global therapy regimens, the expansion of generic and specialty drug pipelines, and the need for flexible manufacturing capacity that complies with current good manufacturing practice requirements. Pharmaceutical sponsors increasingly rely on contract development and manufacturing organizations for formulation development, analytical testing, technology transfer, scale-up, validation, packaging, and lifecycle management. The sector is also becoming more technically demanding as sponsors pursue high-potency compounds, poorly soluble active pharmaceutical ingredients, pediatric and geriatric-friendly formats, fixed-dose combinations, and controlled-release delivery systems. Competitive advantage now depends on regulatory reliability, quality systems maturity, supply chain resilience, digital manufacturing capabilities, and the ability to move products efficiently from clinical batches to commercial-scale oral solid dosage production.

Transformative Shifts Reshaping Oral Solid Dosage Manufacturing

The oral solid dosage contract manufacturing landscape is undergoing structural change as pharmaceutical companies rebalance internal capacity, diversify supplier networks, and accelerate product development timelines. A major shift is the move from transactional outsourcing toward integrated partnerships that combine formulation science, process development, regulatory documentation, analytical services, and commercial manufacturing under one quality framework. Demand for containment-enabled facilities is rising as more small-molecule pipelines include potent compounds requiring occupational exposure control and specialized handling. At the same time, continuous manufacturing, advanced granulation technologies, automated inspection, and real-time process monitoring are gaining attention because they can improve batch consistency, reduce deviations, and support faster scale-up when implemented within validated quality systems. Supply chain strategy is also changing, with sponsors evaluating geographic redundancy, dual sourcing, regional packaging, and qualified backup capacity to reduce disruption risk. Regulatory expectations around data integrity, contamination control, nitrosamine risk assessment, and traceable documentation are pushing manufacturers to strengthen quality governance across every stage of oral solid dosage production.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating a cumulative impact across oral solid dosage contract manufacturing by improving decision-making in formulation design, process optimization, predictive quality, and operational planning. In development workflows, AI-enabled modeling can help screen excipient compatibility, predict dissolution behavior, and identify critical material attributes and process parameters earlier in the lifecycle. In manufacturing operations, machine learning can support deviation pattern detection, predictive maintenance, yield improvement, and more effective root-cause analysis when integrated with validated manufacturing execution systems, laboratory information systems, and process analytical technology. AI also strengthens supply chain control by improving demand signal analysis, inventory planning, and risk identification for critical raw materials and packaging components. However, adoption must be governed by validated algorithms, human oversight, cybersecurity controls, audit trails, and regulatory documentation that demonstrates transparency and reproducibility. For contract manufacturers, the practical value of AI lies not in replacing established quality systems but in augmenting scientific judgment, accelerating investigations, and enabling more consistent oral solid dosage production under compliant operating conditions.

Key Regional Insights Across Global Manufacturing Hubs

Asia-Pacific is a major hub for oral solid dosage contract manufacturing due to its large pharmaceutical production base, expanding skilled workforce, and strong demand for generic medicines across domestic and export markets. The region benefits from established active pharmaceutical ingredient ecosystems, increasing investment in GMP-compliant facilities, and growing expertise in tablets, capsules, modified-release formulations, and high-volume production. Europe is defined by mature quality standards, advanced formulation know-how, and strong regulatory expectations for serialization, pharmacovigilance documentation, qualified person oversight, and manufacturing traceability. North America remains highly influential because of its stringent regulatory environment, deep clinical development activity, and demand for complex formulation support, technology transfer, and commercial manufacturing close to end markets. Latin America is gaining relevance as regional healthcare access expands and manufacturers strengthen capabilities for branded generics, solid dose packaging, and localized supply. Africa is an emerging opportunity area where demand is supported by population growth, access-to-medicine initiatives, and efforts to build more resilient local and regional pharmaceutical supply chains, although infrastructure, regulatory harmonization, and technical capacity vary significantly across countries. The Middle East is prioritizing pharmaceutical localization, healthcare security, and technology partnerships, creating opportunities for oral solid dosage production, secondary packaging, and regional distribution.

Key Group Insights for Strategic Manufacturing Alignment

NATO member countries, while not a pharmaceutical trade bloc, are increasingly relevant from a supply security perspective as governments assess medicine availability, strategic reserves, and manufacturing continuity for critical healthcare needs. The G7 continues to influence high-standard outsourcing practices through advanced regulatory expectations, innovation-driven drug development, strong inspection cultures, and demand for resilient, transparent pharmaceutical supply chains. BRICS countries represent a broad base of pharmaceutical manufacturing capability and medicine consumption, combining large patient populations, generic medicine demand, domestic industrial policy, and growing technical expertise in formulation and process scale-up. The European Union provides one of the most sophisticated regulatory environments for oral solid dosage products, with strong emphasis on GMP compliance, qualified person oversight, serialization, data integrity, and harmonized market authorization procedures. ASEAN is becoming increasingly important for oral solid dosage contract manufacturing as member economies develop pharmaceutical industrial parks, strengthen regulatory cooperation, and support regional production of essential medicines and generics. The GCC is advancing pharmaceutical localization through healthcare investment, procurement reforms, and industrial diversification programs, creating demand for partners with validated oral solid dosage manufacturing, packaging, and quality transfer capabilities.

Key Country Insights Shaping Outsourcing Decisions

China has deep manufacturing scale, API integration, and expanding capabilities in finished oral solid dosage production under upgraded quality systems and stricter regulatory alignment with international standards. The United States is a leading demand center for oral solid dosage contract manufacturing, supported by extensive drug development activity, rigorous regulatory oversight, and ongoing interest in domestic or nearshore supply resilience. Japan requires high quality, documentation precision, and patient-centric dosage standards, creating demand for specialized manufacturing, formulation refinement, and lifecycle support. India is a central global supplier of generic oral solid dosage medicines, supported by extensive formulation expertise, regulatory filing experience, and large-scale manufacturing infrastructure. Germany is recognized for strong engineering, pharmaceutical quality systems, and advanced production capabilities, while the United Kingdom remains important for formulation development, clinical trial supply, regulatory science, and specialized manufacturing expertise. Australia provides a well-regulated environment for pharmaceutical production, clinical supply, and regional distribution, while France supports high-standard pharmaceutical manufacturing and regulatory compliance across solid dose formats. South Korea combines advanced industrial infrastructure, strong quality systems, and growing capability in pharmaceutical development and manufacturing services. Italy and Spain remain important European production bases with experience in contract manufacturing, packaging, and export-oriented pharmaceutical operations. Canada offers a stable regulatory and clinical research environment, with opportunities in specialized solid dose development, packaging, and North American supply support. Russia has emphasized domestic pharmaceutical production capacity and supply autonomy, particularly for essential medicines. Brazil is a key Latin American pharmaceutical market with demand for generics, branded generics, and local manufacturing partnerships, while Mexico benefits from proximity to the United States, established pharmaceutical manufacturing activity, and growing relevance in nearshoring strategies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize quality-led differentiation by investing in robust contamination control, data integrity systems, deviation management, and audit readiness across oral solid dosage operations. Manufacturers should expand capabilities in complex solid dose formats, including modified-release tablets, multiparticulates, high-potency products, fixed-dose combinations, and poorly soluble compounds, as these areas require deeper technical expertise than standard immediate-release production. Sponsors and manufacturers should establish integrated technology transfer models with clear critical quality attributes, process parameters, analytical methods, and validation responsibilities defined early. Supply resilience should be strengthened through qualified secondary suppliers, regional packaging options, dual-site strategies, and transparent material risk assessments. Digital transformation should focus on validated systems that improve batch record accuracy, process visibility, predictive maintenance, and regulatory traceability. Leaders should also invest in workforce training for GMP compliance, containment operations, analytical science, and digital tools, since technical talent remains central to reliable contract manufacturing performance.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed industry intelligence from regulatory guidance, pharmaceutical manufacturing standards, public health agencies, trade documentation, scientific literature, and publicly available industry disclosures. The analysis emphasizes qualitative market dynamics rather than numerical market estimation, sizing, share assessment, or forecasting. Research inputs are reviewed for relevance to oral solid dosage contract manufacturing, including formulation development, GMP compliance, quality systems, supply chain resilience, regional manufacturing capability, regulatory expectations, and emerging technology adoption. Regional, group, and country insights are synthesized through comparative assessment of pharmaceutical production environments, regulatory maturity, healthcare access priorities, outsourcing drivers, and supply security initiatives. Findings are validated through cross-source consistency checks to ensure that conclusions reflect documented industry trends and operational realities.

Conclusion

Oral solid dosage contract manufacturing is evolving from a capacity-based outsourcing service into a strategic, quality-driven partnership model that supports complex formulations, resilient supply chains, and accelerated product lifecycle execution. The strongest opportunities are linked to technical specialization, regulatory excellence, digital manufacturing, and the ability to provide integrated development-to-commercial services. Artificial intelligence, advanced process monitoring, and improved data systems are expected to enhance operational reliability when implemented within validated compliance frameworks. Regional dynamics show that established manufacturing centers remain essential, while emerging hubs are gaining importance through localization, healthcare investment, and supply security priorities. For pharmaceutical sponsors and contract manufacturers, long-term success will depend on aligning scientific capability, quality culture, geographic flexibility, and transparent execution across the global oral solid dosage value chain.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oral Solid Dosage Contract Manufacturing Market, by Form Type
7.1. Introduction
7.2. Tablets
7.2.1. Chewable Tablets
7.2.2. Sublingual Tablets
7.3. Capsules
7.3.1. Hard Gelatin Capsules
7.3.2. Soft Gelatin Capsules
7.4. Powders
7.4.1. Bulk Powders
7.4.2. Sachets
7.5. Granules
7.6. Pellets
8. Oral Solid Dosage Contract Manufacturing Market, by Therapeutic Area
8.1. Introduction
8.2. Anti Infectives
8.2.1. Antibiotics
8.2.2. Antivirals
8.3. Cardiovascular
8.3.1. Hyperlipidemia
8.3.2. Hypertension
8.4. Central Nervous System
8.4.1. Depression
8.4.2. Epilepsy
8.5. Gastrointestinal
8.5.1. Acid Reducers
8.5.2. Prokinetics
8.6. Oncology
8.6.1. Hematological
8.6.2. Solid Tumor
9. Oral Solid Dosage Contract Manufacturing Market, by Stage
9.1. Introduction
9.2. Clinical Trial
9.3. Commercial
10. Oral Solid Dosage Contract Manufacturing Market, by Service Type
10.1. Introduction
10.2. Formulation Development
10.2.1. Preformulation Studies
10.2.2. Prototype Development
10.3. Process Development
10.3.1. Granulation Process Development
10.3.2. Compression Process Development
10.4. Analytical Development
10.4.1. Stability Testing
10.4.2. Dissolution Testing
10.5. Tech Transfer Services
10.6. Commercial Manufacturing Services
11. Oral Solid Dosage Contract Manufacturing Market, by Application
11.1. Introduction
11.2. New Drug Development
11.3. Generic Drug Manufacturing
11.4. Reformulation Services
11.5. Lifecycle Management
12. Oral Solid Dosage Contract Manufacturing Market, by End User
12.1. Introduction
12.2. Biotechnology Companies
12.3. Academic & Research Institutes
12.4. Virtual Pharma Companies
12.5. Pharmaceutical Companies
13. Oral Solid Dosage Contract Manufacturing Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Oral Solid Dosage Contract Manufacturing Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Oral Solid Dosage Contract Manufacturing Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Acino International AG
17.2. Aenova Group GmbH
17.3. Alcami Corporation
17.4. Alkem Laboratories Ltd.
17.5. Almac Group Ltd.
17.6. Aurobindo Pharma Ltd.
17.7. Beximco Pharmaceuticals Ltd.
17.8. Boehringer Ingelheim International GmbH
17.9. Bora Pharmaceuticals Co., Ltd.
17.10. Cambrex Corporation
17.11. Cipla Ltd.
17.12. Corden Pharma International GmbH
17.13. Delpharm SAS
17.14. Divi’s Laboratories Ltd.
17.15. Dr. Reddy’s Laboratories Ltd.
17.16. Famar S.A.
17.17. Fareva SA
17.18. Granules India Ltd.
17.19. Hermes Pharma GmbH
17.20. Hetero Drugs Ltd.
17.21. Jubilant Pharmova Ltd.
17.22. Lonza Group AG
17.23. NextPharma Technologies Holding Ltd.
17.24. PCI Pharma Services LLC
17.25. Pfizer Inc.
17.26. Piramal Pharma Ltd.
17.27. Recipharm AB
17.28. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CHEWABLE TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SUBLINGUAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HARD GELATIN CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SOFT GELATIN CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BULK POWDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BULK POWDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BULK POWDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL SACHETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SACHETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SACHETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GRANULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL GRANULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL GRANULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL PELLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL PELLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL PELLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI INFECTIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI INFECTIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI INFECTIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HYPERLIPIDEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HYPERTENSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HYPERTENSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HYPERTENSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL DEPRESSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL DEPRESSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL DEPRESSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL EPILEPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL EPILEPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL EPILEPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL GASTROINTESTINAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GASTROINTESTINAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GASTROINTESTINAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ACID REDUCERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ACID REDUCERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ACID REDUCERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PROKINETICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PROKINETICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PROKINETICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HEMATOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HEMATOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HEMATOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL CLINICAL TRIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL CLINICAL TRIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CLINICAL TRIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL COMMERCIAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL COMMERCIAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL COMMERCIAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL FORMULATION DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PREFORMULATION STUDIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PROTOTYPE DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL GRANULATION PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL COMPRESSION PROCESS DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ANALYTICAL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL STABILITY TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL STABILITY TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL STABILITY TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL DISSOLUTION TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL TECH TRANSFER SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL COMMERCIAL MANUFACTURING SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL NEW DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL GENERIC DRUG MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL REFORMULATION SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL LIFECYCLE MANAGEMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL VIRTUAL PHARMA COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 169. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 170. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 171. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 172. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 173. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 174. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 175. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 176. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 177. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 178. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 179. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 180. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 181. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 182. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 183. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 184. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 185. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. EUROPE ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 224. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 225. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 226. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 227. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 228. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 229. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 230. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 231. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 232. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 233. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 234. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 235. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 236. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 237. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 238. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 239. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 240. AFRICA ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 246. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 259. GLOBAL ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 260. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 261. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 262. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 263. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 264. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 265. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 266. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 267. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 268. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 269. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 270. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 271. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 272. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 273. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 274. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 275. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 276. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 277. NATO ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 279. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 280. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 281. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 282. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 283. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 284. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 285. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 286. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 287. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 288. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 289. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 290. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 291. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 292. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 293. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 294. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 295. G7 ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 296. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 297. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 298. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 299. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 300. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 301. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 302. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 303. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 304. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 305. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 306. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ONCOLOGY, 2017-2032 (USD MILLION)
TABLE 307. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY STAGE, 2017-2032 (USD MILLION)
TABLE 308. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2017-2032 (USD MILLION)
TABLE 309. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORMULATION DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 310. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY PROCESS DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 311. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANALYTICAL DEVELOPMENT, 2017-2032 (USD MILLION)
TABLE 312. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. BRICS ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY FORM TYPE, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY TABLETS, 2017-2032 (USD MILLION)
TABLE 317. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CAPSULES, 2017-2032 (USD MILLION)
TABLE 318. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY POWDERS, 2017-2032 (USD MILLION)
TABLE 319. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 320. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY ANTI INFECTIVES, 2017-2032 (USD MILLION)
TABLE 321. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR, 2017-2032 (USD MILLION)
TABLE 322. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, 2017-2032 (USD MILLION)
TABLE 323. EUROPEAN UNION ORAL SOLID DOSAGE CONTRACT MANUFACTURING MARKET SIZE, BY GASTROINTESTINAL, 2017-2032 (USD MILLION)
TABLE 324. EUROPEAN UNION ORAL SOLID

Companies Mentioned

  • Acino International AG
  • Aenova Group GmbH
  • Alcami Corporation
  • Alkem Laboratories Ltd.
  • Almac Group Ltd.
  • Aurobindo Pharma Ltd.
  • Beximco Pharmaceuticals Ltd.
  • Boehringer Ingelheim International GmbH
  • Bora Pharmaceuticals Co., Ltd.
  • Cambrex Corporation
  • Cipla Ltd.
  • Corden Pharma International GmbH
  • Delpharm SAS
  • Divi’s Laboratories Ltd.
  • Dr. Reddy’s Laboratories Ltd.
  • Famar S.A.
  • Fareva SA
  • Granules India Ltd.
  • Hermes Pharma GmbH
  • Hetero Drugs Ltd.
  • Jubilant Pharmova Ltd.
  • Lonza Group AG
  • NextPharma Technologies Holding Ltd.
  • PCI Pharma Services LLC
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Recipharm AB
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 11.77 Billion
Forecasted Market Value ( USD ) by 2032 $ 19.96 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned28

Related Topics

Related Reports

Pharmaceutical Contract Manufacturing Market - Global Forecast 2026-2032 - Product Image

Pharmaceutical Contract Manufacturing Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Pharmaceutical Contract Manufacturing & Research Services Market - Global Forecast 2026-2032 - Product Image

Pharmaceutical Contract Manufacturing & Research Services Market - Global Forecast 2026-2032

  • Report
  • 190 Pages
  • Global
From
Oral Solid Dosage Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) - Product Image

Oral Solid Dosage Contract Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • Report
  • 190 Pages
  • Global
From
Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product, Mechanism, End Use, Region, and Segment Forecasts, 2026-2033 - Product Image

Oral Solid Dosage Contract Manufacturing Market Size, Share & Trends Analysis Report by Product, Mechanism, End Use, Region, and Segment Forecasts, 2026-2033

  • Report
  • 150 Pages
  • Global
From
Oral Solid Dosage Contract Manufacturing - Global Strategic Business Report - Product Image

Oral Solid Dosage Contract Manufacturing - Global Strategic Business Report

  • Report
  • 172 Pages
  • Global
From

About the Oral Solid Dosage Contract Manufacturing Market

The Oral Solid Dosage Contract Manufacturing market is a subset of the Pharmaceutical Manufacturing industry. It involves the production of oral solid dosage forms, such as tablets, capsules, and powders, for pharmaceutical companies. This type of manufacturing is often outsourced to contract manufacturers, who specialize in the production of these products. Contract manufacturers provide a range of services, including formulation development, process optimization, and quality control. They also provide packaging and labeling services, as well as regulatory support. This type of manufacturing is highly regulated, and contract manufacturers must adhere to strict quality standards. Some companies in the Oral Solid Dosage Contract Manufacturing market include Patheon, Recipharm, Catalent, and Aenova. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.